These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1756259)

  • 1. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.
    Macheledt JE; Buzdar AU; Hortobagyi GN; Frye DK; Gutterman JU; Holmes FA
    Breast Cancer Res Treat; 1991 Aug; 18(3):165-70. PubMed ID: 1756259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
    Chiesa MD; Passalacqua R; Michiara M; Franciosi V; Di Costanzo F; Bisagni G; Camisa R; Buti S; Tomasello G; Cocconi G;
    Acta Biomed; 2007 Dec; 78(3):204-9. PubMed ID: 18330080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Long HJ; Gerstner JG; Windschitl HE
    J Clin Oncol; 1988 May; 6(5):825-31. PubMed ID: 3284975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
    Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
    J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Tschetter LK; Long HJ; Gerstner JG; Windschitl HE
    Cancer; 1991 Feb; 67(4):886-91. PubMed ID: 1991261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial.
    Amoroso D; Boccardo F; Balestrero M; Miglietta L; Brema F; Cellerino R; Farris A; Folco U; Iacobelli S; Mesiti M
    Breast Cancer Res Treat; 1995 Mar; 33(3):265-8. PubMed ID: 7749154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
    Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
    Ingle JN; Mailliard JA; Schaid DJ; Krook JE; Gesme DH; Windschitl HE; Pfeifle DM; Etzell PS; Gerstner JG; Long HJ
    Cancer; 1991 Jul; 68(1):34-9. PubMed ID: 2049750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
    Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
    Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of tamoxifen related to estrogen receptor level.
    Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
    Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study.
    Recchia F; Sica G; de Filippis S; Discepoli S; Rea S; Torchio P; Frati L
    J Interferon Cytokine Res; 1995 Jul; 15(7):605-10. PubMed ID: 7553230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer.
    Repetto L; Giannessi PG; Campora E; Pronzato P; Vigani A; Naso C; Spinelli I; Conte PF; Rosso R
    Breast Cancer Res Treat; 1996; 39(2):235-8. PubMed ID: 8872332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate.
    Kellokumpu-Lehtinen P; Huovinen R; Johansson R
    Cancer; 1987 Nov; 60(10):2376-81. PubMed ID: 3664426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
    Bernengo MG; Doveil GC; Bertero M; Quaglino P; Fierro MT; Savoia P; Appino A; Colonna S
    Melanoma Res; 1996 Jun; 6(3):257-65. PubMed ID: 8819129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.